PReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics by V Remy Piccolo et al.
POSTER PRESENTATION Open Access
PReS-FINAL-2111: Cytomegalovirus, Epstein Barr
virus and Varicella-Zoster virus infections in
children with juvenile idiopathic arthritis treated
with biologics
V Remy Piccolo*, S Sotou-Bere, A Woerner, R Mouy, B Florkin, B Bader-Meunier, P Quartier
From 20th Pediatric Rheumatology European Society (PReS) Congress
Ljubljana, Slovenia. 25-29 September 2013
Introduction
Varicella-Zoster (VZV) virus, Cytomegalovirus (CMV) and
Epstein Barr virus (EBV) infections may have a severe
course in patients on immunosuppressive treatments.
Data in Juvenile Idiopathic Arthritis (JIA) patients on
biologics are still limited.
Objectives
To assess the outcome of JIA children with VZV, CMV
or EBV infection.
Methods
We conducted a retrospective analysis of the notes of
JIA patients followed between 2006 and 2013 in the
French National reference centre for Juvenile Arthritis
who developed CMV, EBV or VZV infection while on
biologic treatment.
Results
Ten 3 to 16-year-old children were included for VZV
(n = 8), CMV (n = 2) or EBV (n = 1) primoinfection
while on etanercept (n = 1), adalimumab (n = 2), ana-
kinra (n = 2) or canakinumab (n = 6). Seven patients
had concomitant non-steroidal anti-inflammatory
(NSAID) treatment, 7 low dose predniso(lo)ne and
4 methotrexate. The 8 patients with VZV infection
developed typical skin disease and marked systemic
symptoms in some cases, however there was no visceral
involvement. Nsaids and steroids were interrupted in all
cases. Biologic therapy was interrupted in 7 cases for 5
to 150 days. One patient was treated with acyclovir IV
and 3 with valacyclovir for 5 to 15 days. The 2 patients
who developed primary CMV infection disclosed
marked increase of transaminases and moderate increase
of gamma glutamyl transferase for 3 weeks; one patient
remained asymptomatic and the other one had mild
digestive symptoms. Both were on canakinumab and the
following injection was postponed. The patient with
primary EBV infection developed a rash with fever,
hepatomegaly and splenomegaly that resolved after
2 months while NSAID and biologic treatment had been
interrupted and corticosteroid treatment prescribed in
order to control disease activity. No patient developed
macrophage activation syndrome and the 10 patients
had a favorable outcome without sequellae.
Conclusion
In JIA children on biologic, VZV, CMV and EBV infec-
tions may result in marked systemic symptoms in some
cases, however patients outcome was favorable in this
small series while NSAID treatment was systematically
stopped, anti-viral therapy prescribed in some VZV infec-
tions and biologic therapy continued or only transiently
interrupted.
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